Man­u­fac­tur­ing roundup: Cel­l­Vax part­ners up with Ther­a­gent for PhII tri­al; Ox­ford Bio­med­ica sells fa­cil­i­ty for $70M+

The cell ther­a­py CD­MO Ther­a­gent has roped in a man­u­fac­tur­ing con­tract for a Phase II tri­al.

The com­pa­ny is work­ing on Cel­l­Vax Ther­a­peu­tics’ im­munother­a­py can­di­date FK-PC101, a cell-based au­tol­o­gous can­cer vac­cine for prostate can­cer pa­tients who have a high rate of re­cur­rence af­ter prosta­te­c­to­my. The size of the deal was not dis­closed.

In an email to End­points News, Ther­a­gent COO Jeff Mas­ten said the CD­MO was se­lect­ed af­ter a con­sul­tant’s rec­om­men­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER